Katz, Zachary B.
Zhang, Chen http://orcid.org/0000-0001-7148-8881
Quintana, Ariel
Lillemeier, Björn F.
Hogan, Patrick G.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32 CA009370)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (T32 AI125179, AI084167)
NOMIS Stiftung
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM110397, GM110397)
Article History
Received: 5 March 2019
Accepted: 28 June 2019
First Online: 25 July 2019
Competing Interests
: PGH is a founder of CalciMedica, Inc, and a member of its scientific advisory board. CalciMedica has developed specific CRAC channel inhibitors intended for treatment of inflammatory and immune disorders. CalciMedica has no scientific or commercial interest in the work reported here, but we are disclosing this affiliation in accordance with NIH guidelines. The other authors declare no competing interests.